title: Remote Controlled CARs: Towards a Safer Therapy for Leukemia.
abstract: Genetic engineering of patient T cells with chimeric antigen receptors (CAR T cells) provides a powerful tool for inducing remissions in patients with various cancers derived from B cells. Challenges stemming from the inability to control the CAR T cells once given pose significant safety concerns. An article in Cancer Immunology Research presents an approach to circumvent this issue. Cancer Immunol Res; 4(8); 643. ©2016 AACRSee article by Sakemura et al., p. 658.
authors.affiliation: Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. cjune@exchange.upenn.edu.
authors.forename: Carl H
authors.initials: CH
authors.lastname: June
mesh_terms: D018941:Antigens, CD19; D006801:Humans; D016219:Immunotherapy, Adoptive; D007938:Leukemia; D011948:Receptors, Antigen, T-Cell; D000076962:Receptors, Chimeric Antigen
chemical_list: D018941:Antigens, CD19; D011948:Receptors, Antigen, T-Cell; D000076962:Receptors, Chimeric Antigen